Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.64 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11787429 | 0.98 | CYP4F2 (0.66) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL5855704 | 0.83 | CYP4F2 (0.64) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL4917937 | 0.82 | CYP4F2 (0.67) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL23309176 | 0.78 | CYP4F2 (1.00) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL14960350 | 0.77 | CYP4F2 (0.61) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL21068275 | 0.77 | CYP4F2 (0.60) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL20730211 | 0.77 | CYP4F2 (0.97) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL14211505 | 0.77 | CYP4F2 (0.56) | CYP4F2CYP4A11TSHRNAAAALDH1A1 | |
| SCHEMBL22190510 | 0.75 | CYP4F2 (0.71) | CYP4F2CYP4A11PPARAABCB11CYP1A2 | |
| SCHEMBL195662 | 0.75 | CYP4F2 (0.56) | CYP4F2CYP4A11PPARAABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | CYP4F2 633/4885CYP4A11 118/4885PPARA 464/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | CYP4F2 733/4885CYP4A11 118/4885PPARA 579/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885PPARA 660/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP4F2 727/4885CYP4A11 126/4885PPARA 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.